<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PRESENT (Physicians' Routine Evaluation of Safety &amp; Efficacy of NovoMix 30 Therapy) is a 6-month observational study of safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in 31,044 type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients from 15 countries </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this article is to describe the study protocol and assess baseline characteristics of patients in various countries according to <z:mp ids='MP_0002055'>diabetes</z:mp> duration (&lt;5 years, 5 to &lt;or=10 years, 10 to &lt;or=20 years and &gt;or=20 years), to improve treatment decisions in clinical practice </plain></SENT>
<SENT sid="2" pm="."><plain>Glycaemic control was similar across <z:hpo ids='HP_0000001'>all</z:hpo> groups: HbA1c 9.3-9.4%; fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> 11.3-11.6 mmol/L; postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> 15.9-16.3 mmol/L </plain></SENT>
<SENT sid="3" pm="."><plain>Major <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> was reported by 5% of <z:hpo ids='HP_0000001'>all</z:hpo> patients, minor <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> increased with <z:mp ids='MP_0002055'>diabetes</z:mp> duration (25.4-30.3%); overall <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> rate was 6.7 events/patient/year </plain></SENT>
<SENT sid="4" pm="."><plain>Complications increased with <z:mp ids='MP_0002055'>diabetes</z:mp> duration; the most reported were <z:hpo ids='HP_0000822'>hypertension</z:hpo> (40.6-71.0%) and <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e> (39.4-56.6%) </plain></SENT>
<SENT sid="5" pm="."><plain>Of patients 38% previously received OADs only, 28% insulin only, 19% insulin with OADs, and 13% received no therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Glycaemic control appeared independent of <z:mp ids='MP_0002055'>diabetes</z:mp> duration </plain></SENT>
<SENT sid="7" pm="."><plain>HbA1c was well above targets and the clinical inertia was quite apparent; even patients with <z:mp ids='MP_0002055'>diabetes</z:mp> for &lt;5 years had high HbA1c levels </plain></SENT>
<SENT sid="8" pm="."><plain>Patients suffered high rates of complications and <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> before starting BIAsp 30 therapy </plain></SENT>
</text></document>